Double down.

Initial reporting of the landmark KEYNOTE-189 trial brought pembrolizumab to the first-line for wild-type non-small cell lung cancer (NSCLC) after proving improvements in survival across all PD-L1 statuses when added to chemo. Nearly two years later we have updated reporting with median follow-up extended from 11 to 23 months. And it’s lost no shock value with time. Median survival with upfront pembro clocked in at double that with chemo alone: 22 versus 11 months, respectively. And, again, a significant (in any sense of the word) survival advantage persisted for all, including no, PD-L1 expression with no difference in G3-5 toxicity rates. TBL: First-line pembro has transformed the landscape of wild-type NSCLC. | Gadgeel, J Clin Oncol 2020